Abstract

Positron emission tomography (PET) using 2-deoxy-2-[18F]fluoro-d-glucose (FDG) is one of the most important advances in oncologic imaging. FDG has provided researchers and clinicians with an insight into cancer biology by exploring glucose metabolism in vivo and in defining the patient’s tumour phenotype. Despite progress in radiopharmaceutical development and imaging technology exploring other molecular and cellular pathways, FDG remains the most widely used radiolabelled tracer for PET imaging worldwide. Molecular imaging with FDG PET is now an integral part of multidisciplinary cancer care. The use of FDG PET in determining appropriate treatments at initial diagnosis, during and following therapy, is a vital component in developing personalised medicine at various time points in a patient’s battle against cancer. In this chapter, we shall discuss briefly the background of FDG as a radiopharmaceutical and its applications in clinical oncology.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.